This study focuses on Upadacitinib, a new oral and small-molecular medication that inhibits specific enzymes involved in inflammation. The goal is to determine efficacy and safety of Upadacitinib for Crohn's Disease patients in China compared with Vedolizumab, which is used to inhibit recruitment of inflammatory cells. Crohn's Disease significantly affects individuals' quality of life and imposes a high burden on society and healthcare systems. Current treatments don't work for everyone, and some patients may need surgery. Upadacitinib has shown promise in other countries for treating Crohn's Disease and related conditions, and has been approved by the US FDA for such use. The investigators' retrospective and multicenter study looks back at patient records from multiple hospitals to analyze the outcomes of those who have received Upadacitinib and Vedolizumab. Investigators aim to enroll patients treated between January 2020 and March 2024, who received follow-up for more than 12 weeks. For patients, families, and healthcare providers, this research could provide a potential new treatment option for Crohn's Disease. Better efficacy and safety of Upadacitinib than Vedolizumab could lead to better management of the disease, possibly reducing the need for surgery and improving the quality of life. The ultimate goal is to provide more personalized and effective treatment strategies for Crohn's Disease patients in China.
This retrospective, multicenter study is designed to compare the efficacy and safety of Upadacitinib and Vedolizumab in second-line treatment for Crohn's Disease, the former is an oral selective enzyme inhibitor, and the latter is a monoclonal antibody targeting integrin α4β7. Crohn's Disease poses a significant impact on the quality of life for individuals and presents a considerable challenge to healthcare systems due to the societal burdens it incurs. While current therapeutic interventions offer relief, these interventions fail to suffice for all patients, with some requiring surgical intervention. Despite the approval of Upadacitinib by the US FDA and its promising application in other nations for Crohn's Disease management, there is a scarcity of data on its effectiveness and safety among Chinese patients. The investigators' research aims to fill this knowledge gap by retrospectively analyzing patient records from multiple hospitals across China. The study targets the adult patients that has received follow-up for more than 12 weeks between January 2020 and March 2024. By assessing the outcomes of these patients, the investigators' objective is to ascertain the potential of Upadacitinib as a viable treatment alternative, which may revolutionize the current Crohn's Disease treatment paradigm in China.The implications of this study are significant for patients, their families, and healthcare providers, as it could herald a new therapeutic avenue for Crohn's Disease management. A clearer understanding of Upadacitinib's role in disease control could enhance patient care by decreasing the necessity for surgical procedures and ameliorating life quality for Crohn's Disease sufferers. The overarching ambition of this research is to pave the way for more individualized and efficacious treatment methodologies for the Crohn's Disease patient populace in China.
Study Type
OBSERVATIONAL
Enrollment
172
the Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Steroid-Free Clinical Remission
Steroid-Free Clinical Remission in Crohn's Disease is defined as a Crohn's disease activity index(CDAI) score of less than 150, achieved without the use of corticosteroids.
Time frame: Upadacitinib group: assessed at 12 weeks; Vedolizumab group: assessed at 14 weeks;
Clinical Remission
Clinical Remission in Crohn's Disease is defined as a Crohn's disease activity index(CDAI) score of less than 150
Time frame: Upadacitinib group: assessed at 12 weeks; Vedolizumab group: assessed at 14 weeks;
Clinical Response
Clinical Response in Crohn's Disease is a decrease in Crohn's disease activity index(CDAI) score by 70 points or more from baseline.
Time frame: Upadacitinib group: assessed at 12 weeks; Vedolizumab group: assessed at 14 weeks;
Endoscopic Remission
A simple endoscopic score for Crohn's disease(SES-CD) score of 2 or less indicates endoscopic remission
Time frame: Upadacitinib group: assessed at 12 weeks; Vedolizumab group: assessed at 14 weeks;
Endoscopic Response
Endoscopic Response in Crohn's Disease is a decrease in simple endoscopic score for Crohn's disease(SES-CD) score by 50 percent or more from baseline.
Time frame: Upadacitinib group: assessed at 12 weeks; Vedolizumab group: assessed at 14 weeks;
Mucosal Healing
A simple endoscopic score for Crohn's disease(SES-CD) score of 0 is indicative of mucosal healing
Time frame: Upadacitinib group: assessed at 12 weeks; Vedolizumab group: assessed at 14 weeks;
Radiological Remission
Defined as the complete disappearance or minimization of intestinal inflammation on imaging studies, signifying no visible lesions, normalized wall thickness, absence of strictures or obstructions, and no new areas of disease. Radiographic remission is an important indicator of deep remission in disease treatment goals.
Time frame: Upadacitinib group: assessed at 12 weeks; Vedolizumab group: assessed at 14 weeks;
Radiological Response
Typically defined as a significant reduction in the size of affected areas, decreased wall thickness, and decreased markers of inflammation observed through imaging methods such as MRI or CT scans. A radiographic response indicates a reduction in disease activity but may not represent complete disease remission.
Time frame: Upadacitinib group: assessed at 12 weeks; Vedolizumab group: assessed at 14 weeks;
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.